Azithromycin in high ‐risk, refractory chronic rhinosinusitus after endoscopic sinus surgery and corticosteroid irrigations: a double‐blind, randomized, placebo‐controlled trial

ConclusionLow ‐dose azithromycin is a therapeutic option with few side effects. Its use can show favorable clinical outcomes in this difficult‐to‐treat population, especially if patients are AERD‐negative.

Source: International Forum of Allergy and Rhinology - March 23, 2021 Category: Allergy & Immunology Authors: Anastasios Maniakas, Marc ‐Henri Asmar, Axel Eluid Renteria, Smriti Nayan, Saud Alromaih, Leandra Mfuna Endam, John Sam Sampalis, Martin Desrosiers Tags: ORIGINAL ARTICLE Source Type: research